GeneNews Reports Positive Results From Colorectal Cancer Study

Armen Hareyan's picture

GeneNews reported positive performance results from a large validation study of a six-gene biomarker panel for the assessment of a patient's current risk for colorectal cancer. This panel forms the basis of the Company's lead product, ColonSentry, which is planned for launch in Canada in the third quarter of 2008 as a laboratory-developed test.


The validation study confirmed (p less than 0.05) that the panel was able to stratify a population with average risk for colorectal cancer into three groups:


Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.